Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITS-LONG long-term rituximab in psychotic disorders
2026-525324-26-00Phase 2Authorised
- Sponsor
- Region Örebro län
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Schizophrenia Spectrum and Other Psychotic Disorders (SZ), schizophrenia and schizoaffective disorder, sponsored by Region Örebro län. Primary endpoint: Primary clinical improvement (CGI-I at 4 months). Planned start Jun 2026; status: authorised.
02
Drugs
rituximab
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2026-525324-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525324-26-00.